ADT1758-Human Anti-PD-1xCTLA-4 Bispecific Antibody
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1758 |
Product Name |
ADT1758-Human Anti-PD-1xCTLA-4 Bispecific Antibody |
Isotype |
Human IgG1-Kappa |
Clonity |
Monoclonal |
|
Alternate Names Human Anti-PD-1 mAb, Anti-PD-1 Monoclonal Antibody, PD-1 recombinant antibody, Anti-PD-1 Bispecific Antibody, Human Anti-CTLA-4 mAb, CTLA-4 recombinant antibody, Anti-CTLA-4 Monoclonal Antibody, Anti-CTLA-4 Bispecific Antibody |
|
Official Symbol |
PD-1xCTLA-4 |
Target 1 |
PD-1 |
Gene ID 1 |
5133 |
Target 2 |
CTLA-4 |
Gene 2 |
1493 |
Species |
Human |
Drug Name |
Vudalimab |
CAS Number |
2329669-72-7 |
Endotoxin |
<1EU/mg. Determined by the LAL method. |
Sterility |
0.2 μM filtered. |
Expression Host |
CHO Cells |
Size |
1mg,5mg,50mg,100mg |
Research Area |
Cancer |
Application |
FuncS |
Purity |
>90% |
Concentration |
Batch dependent |
Buffer |
20mM His/Asp, pH 5.0,Contains no stabilizers or preservatives |
Recommended Dilution Buffer |
ABDB-1001 or 20mM His/Asp, pH5.0,Contains no stabilizers or preservatives. |
Storage |
2 weeks, 2-8℃ under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for one-year storage. |
Shipping Condition |
Shipped on ice packs. |
Protocol Information |
Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose-response or titration experiment. |
Note |
For Research Use Only! |
|
Reference 1. Ribas et al. (2015). Cell. DOI: 10.1016/j.cell.2015.07.030
2. Sharma et al. (2021). Cell. DOI: 10.1016/j.cell.2021.03.035
3. Leach et al. (1996). Science. DOI: 10.1126/science.272.5260.1737
|
FAQ
-
+ -
What are PD-1 and CTLA-4?
PD-1 and CTLA-4 are immune checkpoint proteins that suppress T-cell activity. Dual blockade enhances anti-tumor immune responses.
-
+ -
How can I obtain Request Quote of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
Why combine PD-1 and CTLA-4 targeting?
This bispecific antibody amplifies immune activation, potentially improving efficacy compared to single-checkpoint inhibitors. -
+ -
How do bispecific antibodies differ from monoclonal antibodies?
Unlike monoclonal antibodies (targeting one antigen), BsAbs engage two targets, facilitating dual-pathway inhibition, immune cell recruitment, or bridging cells (e.g., T-cells and tumor cells).